(Total Views: 581)
Posted On: 08/27/2024 5:13:05 PM
Post# of 154899
What about combining leronlimab with a LAG-3 inhibitor?
By way of comparison, in MSS mCRC, interim results of a Phase I trial of Merck's LAG3 candidate (favezelimab) combined with pembrolizumab revealed a 6.3% Overall Response Rate and 8.3 month Overall Survival (12.7 months in patients with high PD-L1 expression, 6.7 months for patients with low expression). Not particularly good--leronlimab should do much better--but they are moving forward with a Phase III study.
In metastatic breast cancer, Immutep (IMMP--another immune-oncology penny stock) is combining their LAG3 inhibitor eftilagimod alpha (efti) with placitaxel in a Phase IIb/III trial. Notably, one of their Triple Negative MBC patients had a complete response to the combination. I think the LAG3 inhibitors--especially efti--bear watching... both as competition (!), and as an advance in cancer treatment that substantially increases the efficacy of checkpoint inhibitors in those cancer patients with low PD1/PD-L1 expression.
By way of comparison, in MSS mCRC, interim results of a Phase I trial of Merck's LAG3 candidate (favezelimab) combined with pembrolizumab revealed a 6.3% Overall Response Rate and 8.3 month Overall Survival (12.7 months in patients with high PD-L1 expression, 6.7 months for patients with low expression). Not particularly good--leronlimab should do much better--but they are moving forward with a Phase III study.
In metastatic breast cancer, Immutep (IMMP--another immune-oncology penny stock) is combining their LAG3 inhibitor eftilagimod alpha (efti) with placitaxel in a Phase IIb/III trial. Notably, one of their Triple Negative MBC patients had a complete response to the combination. I think the LAG3 inhibitors--especially efti--bear watching... both as competition (!), and as an advance in cancer treatment that substantially increases the efficacy of checkpoint inhibitors in those cancer patients with low PD1/PD-L1 expression.
(6)
(0)
